Overview

Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the efficacy and safety of two different regimens of anti-VEGF Therapy (OCTA plus OCT guided 3+PRN vs. OCT guided 3+PRN) in Chinese patients with PCV. This study is to provide long-term safety data in the treatment of Chinese patients with PCV.

Phase:

Phase 4

Details

Lead Sponsor:

Xiaodong Sun

Collaborators:

Eye & ENT Hospital of Fudan University
Shanghai Zhongshan Hospital

Treatments:

Bevacizumab